Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 13/20 | 0.49 |
| ▸ | HTR2A | P28223 | 3/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12505926 | 0.86 | CYP1A2 (0.48) | CYP1A2CYP2A6MTNR1AHTR2AMTNR1B | |
| SCHEMBL9967888 | 0.86 | CYP1A2 (0.52) | CYP1A2CYP2A6MTNR1AMTNR1B | |
| SCHEMBL16281933 | 0.84 | KIF11 (0.41) | CYP1A2CYP2A6MTNR1AHTR2A | |
| SCHEMBL28873491 | 0.84 | TRPV1 (0.50) | CYP1A2CYP2A6MTNR1AHTR2AMTNR1B | |
| SCHEMBL18428158 | 0.83 | MTNR1A (0.48) | CYP1A2CYP2A6MTNR1AHTR2AMTNR1B | |
| SCHEMBL17187860 | 0.82 | CYP1A2 (0.44) | CYP1A2CYP2A6MTNR1AHTR2AMTNR1B | |
| SCHEMBL29003416 | 0.80 | CA2 (0.36) | MTNR1AHTR2AMTNR1BHTR2CHTR2B | |
| SCHEMBL19700542 | 0.79 | MMP1 (0.38) | CYP1A2CYP2A6HTR2A | |
| SCHEMBL19382614 | 0.76 | CYP1A2 (0.61) | CYP1A2CYP2A6MTNR1AHTR2A | |
| SCHEMBL22349672 | 0.76 | SCN9A (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20210040089-A1 | KRAS MUTANT PROTEIN INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CYP1A2 3955/4885CYP2A6 4169/4885MTNR1A 2526/4885 |
| US-20210040089-A1 | KRAS MUTANT PROTEIN INHIBITORS | KRAS, NRAS, APC | CYP1A2 4199/4885CYP2A6 4153/4885MTNR1A 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.